99 related articles for article (PubMed ID: 2531668)
1. Testicular changes after treatment with a GnRH analog (buserelin) in association with cyproterone acetate in men with prostatic cancer.
Properzi G; Francavilla S; Vicentini C; Cordeschi G; Galassi P; Paradiso Galatioto G; Miano L
Eur Urol; 1989; 16(6):426-32. PubMed ID: 2531668
[TBL] [Abstract][Full Text] [Related]
2. Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects.
Huhtaniemi I; Parvinen M; Venho P; Rannikko S
Int J Androl; 1991 Oct; 14(5):374-86. PubMed ID: 1839022
[TBL] [Abstract][Full Text] [Related]
3. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
4. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne FM
Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
[TBL] [Abstract][Full Text] [Related]
5. Effect of cyproterone acetate on testis of albino rats: ultrastructural and biochemical approach.
Bhiwgade DA; Menon SN; Avari KM
Indian J Exp Biol; 1990 Mar; 28(3):201-7. PubMed ID: 2142122
[TBL] [Abstract][Full Text] [Related]
6. Treatment of prostatic cancer with cyproterone acetate as monotherapy.
Beurton D; Grall J; Davody P; Cukier J
Prog Clin Biol Res; 1987; 243A():369-77. PubMed ID: 2958861
[No Abstract] [Full Text] [Related]
7. [LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
Senn E; Müller J; Alioth H
Schweiz Rundsch Med Prax; 1985 Nov; 74(48):1340-4. PubMed ID: 3003863
[No Abstract] [Full Text] [Related]
8. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Waxman J; Williams G; Sandow J; Hewitt G; Abel P; Farah N; Fleming J; Cox J; O'Donoghue EP; Sikora K
Am J Clin Oncol; 1988; 11 Suppl 2():S152-5. PubMed ID: 2853934
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of prostatic cancer with cyproterone acetate].
Maier U
Wien Klin Wochenschr; 1988 Jan; 100(1):16-9. PubMed ID: 2964127
[TBL] [Abstract][Full Text] [Related]
10. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer.
Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
Am J Clin Oncol; 1988; 11 Suppl 1():S11-5. PubMed ID: 2839028
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of virginal prostatic cancer with cyproterone acetate].
Maier U
Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
[TBL] [Abstract][Full Text] [Related]
12. The different mechanisms for suppression of pituitary and testicular function.
Sandow J; Engelbart K; von Rechenberg W
Med Biol; 1986; 63(5-6):192-200. PubMed ID: 3010006
[TBL] [Abstract][Full Text] [Related]
13. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced carcinoma of the prostate by LHRH-agonists.
Claes HI; Vandenbussche L; Vereecken RL
Prog Clin Biol Res; 1987; 243A():229-37. PubMed ID: 2958853
[No Abstract] [Full Text] [Related]
15. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
Borgmann V; al-Abadi H; Nagel R
Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of advanced cancer of the prostate using LHRH analogs. How can a possible initial flare-up be prevented?].
Bouffioux C; Denis L; Mahler C; de Leval J
Acta Urol Belg; 1986; 54(3):304-8. PubMed ID: 2946208
[No Abstract] [Full Text] [Related]
17. Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs.
Tunn UW; Goldschmidt AJ; Peter K; Becker M
Prog Clin Biol Res; 1990; 359():165-76; discussion 177-80. PubMed ID: 2149458
[No Abstract] [Full Text] [Related]
18. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Di Silverio F; Serio M; D'Eramo G; Sciarra F
Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
[TBL] [Abstract][Full Text] [Related]
19. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy of advanced prostate cancer].
Hofmann W; Langkopf B
Z Urol Nephrol; 1986 Jan; 79(1):33-9. PubMed ID: 2938361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
